IP Library Granted Patent US 7,329,418
Granted Patent B2
US 7,329,418 · App. 11/678,408 · Granted Feb 12, 2008

Pharmaceutical tablets having height greater than width

Assignee: Accu Break Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,329,418
App. No.
11/678,408
Granted
Feb 12, 2008
Kind
B2
Abstract

An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Claims (32)

1. A compressed, immediate-release pharmaceutical tablet containing a therapeutic dose of one or more active pharmaceutical ingredients and having a greater height than width, said height being measured vertically from the top to the bottom of said tablet while it is in the tablet die in which it is fully compressed, after said compression has been completed; and said width being measured as the greatest horizontal dimension of the tablet at a location halfway between said top and said bottom of said tablet, except that when the horizontal cross-section of said tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of said horizontal cross-section, and measuring the length of a line that is at right angle to said shorter sides, said tablet consisting essentially of:

a bottom end segment comprising an immediate-release composition containing at least about half of said therapeutic dose of the one or more active pharmaceutical ingredient, said bottom end segment having an exposed bottom end and a contacting face opposite its exposed bottom end;

a top end segment comprising a composition substantially identical to the composition of said bottom end segment, said top end segment having an exposed top end and a contacting face opposite its exposed top end;

a middle segment located between said bottom end segment and said top end segment, said middle segment comprising a composition consisting essentially of immediate-release excipients and being substantially free of active pharmaceutical ingredient, said middle segment having a bottom face in contact with the contacting face of said bottom end segment, a top face in contact with the contacting face of said top end segment, and an exposed outer side surface; and

optionally, an immediate-release coating substantially free of active pharmaceutical ingredient.

2. The tablet of claim 1 wherein said outer side surface of the middle segment comprises a substantially horizontal score transverse to the vertical axis of the tablet.

3. The tablet of claim 1 wherein the score is positioned such that a plane passing through the score substantially bisects the tablet.

4. The tablet of claim 1 wherein the score is positioned such that a plane passing through the score substantially bisects the height or effective height of the middle segment.

5. The tablet of claim 1 wherein the tablet is uncoated.

6. The tablet of claim 1 wherein said tablet is coated, said coating comprising a water-soluble polymer.

7. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises an active pharmaceutical ingredient selected from the group consisting of warfarin, a statin, risperidone, methotrexate, metformin, atenolol, prednisone, phenytoin, lamotrigine, and meloxicam.

8. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises warfarin.

9. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises a statin.

10. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises methotrexate.

11. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises metformin.

12. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises atenolol.

13. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises phenytoin.

14. The compressed pharmaceutical tablet of claim 1 wherein the bottom end segment comprises lamotrigine.

15. A compressed, immediate-release pharmaceutical tablet containing a therapeutic dose of one or more active pharmaceutical ingredients and having a greater height than width, said height being measured vertically from the top to the bottom of said tablet while it is in the tablet die in which it is fully compressed, after said compression has been completed; and said width being measured as the greatest horizontal dimension of the tablet at a location halfway between said top and said bottom of said tablet, except that when the horizontal cross-section of said tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of said horizontal cross-section, and measuring the length of a line that is at right angle to said shorter sides, said tablet consisting essentially of:

a bottom end segment comprising an immediate-release composition containing at least about half of said therapeutic dose of the one or more active pharmaceutical ingredient, said bottom end segment having an exposed bottom end and a contacting face opposite its exposed bottom end;

a top end segment comprising a composition substantially identical to the composition of said bottom end segment, said top end segment having an exposed top end and a contacting face opposite its exposed top end;

a middle segment located between said bottom end segment and said top end segment, said middle segment comprising a composition consisting essentially of immediate-release excipients and being substantially free of active pharmaceutical ingredient, said middle segment having a bottom face in contact with the contacting face of said bottom end segment, a top face in contact with the contacting face of said top end segment, and an exposed outer side surface, said outer side surface comprising a substantially horizontal score positioned such that a plane passing through said score substantially bisects the tablet or middle segment; and

optionally, an immediate-release coating substantially free of active pharmaceutical ingredient.

16. The tablet of claim 15 wherein said score is positioned such that a plane passing through said score substantially bisects the height of the middle segment.

17. The tablet of claim 15 wherein said score is positioned such that a plane passing through said score substantially bisects the effective height of the middle segment.

18. The tablet of claim 15 wherein said tablet is uncoated.

19. The tablet of claim 14 wherein said tablet is coated, said coating comprising a water-soluble polymer.

20. A compressed, immediate-release pharmaceutical tablet containing a therapeutic dose of one or more active pharmaceutical ingredients and having a greater height than width, said height being measured vertically from the top to the bottom of said tablet while it is in the tablet die in which it is fully compressed after said compression has been completed; and said width being measured as the greatest horizontal dimension of the tablet at a location halfway between said top and said bottom of said tablet, except that when the horizontal cross-section of said tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of said horizontal cross-section, and measuring the length of a line that is at right angle to said shorter sides, said tablet consisting essentially of:

a bottom end segment comprising an immediate-release composition containing at least about half of said therapeutic dose of the one or more active pharmaceutical ingredient, said bottom end segment having an exposed bottom end and a contacting face opposite its exposed bottom end;

a top end segment comprising a composition substantially identical to the composition of said bottom end segment, said top end segment having an exposed top end and a contacting face opposite its exposed top end;

a middle segment located between said bottom end segment and said top end segment, said middle segment comprising a composition consisting essentially of immediate-release excipients and being substantially free of active pharmaceutical ingredient, said middle segment having a bottom face in contact with the contacting face of said bottom end segment, a top face in contact with the contacting face of said top end segment and an exposed outer side surface, said outer side surface comprising printed indicia positioned substantially horizontally such that a plane passing through said printed indicia substantially bisects the tablet or middle segment; and

optionally, an immediate-release coating substantially free of active pharmaceutical ingredient.

Assignments (2)
SECURITY AGREEMENT Recorded Apr 26, 2013
From: ACCU-BREAK TECHNOLOGIES, INC.; ACCU-BREAK PHARMACEUTICALS, INC.
To: HARRIS, MEL
Reel/Frame 030295/0735 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2007
From: SOLOMON, LAWRENCE; KAPLAN, ALLAN S.
To: ACCU-BREAK TECHNOLOGIES, INC.
Reel/Frame 020103/0280 →
Continuity (4)
Continuation In Part 1156934300 · Nov 17, 2006
Continuation In Part 1059830600 · Aug 24, 2006
Continuation In Part 1059826700 · Aug 23, 2006
Related Publication 20070141155A1 · Jun 21, 2007